KRAS mutations are considered one of the initiating genomic processes in the development of pancreatic cancer, causing permanent activation of RAS pathway leading to carcinogenesis and resistance to systemic treatments (30–32). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.